Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filomena De Falco

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cell Death & Disease|September 1, 2022
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLLFilomena De Falco, Chiara Rompietti, Daniele Sorcini, et al.
Leukemia|March 21, 2025
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in miceChiara Rompietti, Francesco Maria Adamo, Daniele Sorcini, et al.
International Journal of Cancer|March 7, 2018
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemiaStefano Baldoni, Beatrice Del Papa, Erica Dorillo, et al.
Frontiers in Oncology|October 11, 2023
<i>NOTCH1</i>-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potentialEstevão Carlos Silva Barcelos, Chiara Rompietti, Francesco Maria Adamo, et al.
Cancers|July 29, 2023
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic LeukemiaFrancesco Maria Adamo, Estevao Carlos Silva Barcelos, Filomena De Falco, et al.
Frontiers in Oncology|May 8, 2018
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem CellsMauro Di Ianni, Stefano Baldoni, Beatrice Del Papa, et al.
Cancers|June 10, 2023
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter StudyFrancesca R Mauro, Diana Giannarelli, Clementina M Galluzzo, et al.
British Journal of Haematology|December 9, 2022
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemiaDaniele Sorcini, Filomena De Falco, Marco Gargaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2019
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic LeukemiaBeatrice Del Papa, Stefano Baldoni, Erica Dorillo, et al.
Frontiers in Oncology|June 14, 2021
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the <i>NOTCH1</i> and <i>IGHV</i> Mutational StatusStefano Baldoni, Beatrice Del Papa, Filomena De Falco, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cell Death & Disease|September 1, 2022
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLLFilomena De Falco, Chiara Rompietti, Daniele Sorcini, et al.
Leukemia|March 21, 2025
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in miceChiara Rompietti, Francesco Maria Adamo, Daniele Sorcini, et al.
International Journal of Cancer|March 7, 2018
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemiaStefano Baldoni, Beatrice Del Papa, Erica Dorillo, et al.
Frontiers in Oncology|October 11, 2023
<i>NOTCH1</i>-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potentialEstevão Carlos Silva Barcelos, Chiara Rompietti, Francesco Maria Adamo, et al.
Cancers|July 29, 2023
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic LeukemiaFrancesco Maria Adamo, Estevao Carlos Silva Barcelos, Filomena De Falco, et al.
Frontiers in Oncology|May 8, 2018
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem CellsMauro Di Ianni, Stefano Baldoni, Beatrice Del Papa, et al.
Cancers|June 10, 2023
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter StudyFrancesca R Mauro, Diana Giannarelli, Clementina M Galluzzo, et al.
British Journal of Haematology|December 9, 2022
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemiaDaniele Sorcini, Filomena De Falco, Marco Gargaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2019
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic LeukemiaBeatrice Del Papa, Stefano Baldoni, Erica Dorillo, et al.
Frontiers in Oncology|June 14, 2021
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the <i>NOTCH1</i> and <i>IGHV</i> Mutational StatusStefano Baldoni, Beatrice Del Papa, Filomena De Falco, et al.
Pageof 2